



www.lsc.ohio.gov

OHIO LEGISLATIVE SERVICE COMMISSION

Office of Research
and Drafting

Legislative Budget
Office

H.B. 135
134th General Assembly

Bill Analysis

[Click here for H.B. 135's Fiscal Note](#)

Version: As Reported by House Health

Primary Sponsors: Reps. Manchester and West

Nick Thomas, Research Analyst

SUMMARY

- Requires health insuring corporations and sickness and accident insurers to apply amounts paid by or on behalf of covered individuals toward cost-sharing requirements.
- Exempts situations where a generic version of a brand name drug exists, but the prescribing physician prescribes the brand name drug without it being medically necessary.

DETAILED ANALYSIS

The bill imposes requirements on how health plan issuers apply amounts paid by or on behalf of a covered individual towards a cost sharing requirement. Under current law, unchanged by the bill, “cost-sharing requirement” refers to any cost to a covered individual for health services according to any coverage limit, copayment, coinsurance, deductible, or other out-of-pocket expense requirement imposed by a health benefit plan.¹ The bill applies to health insuring corporations and sickness and accident insurers.²

Under the bill, health insuring corporations and sickness and accident insurers must include all amounts paid by a covered individual or by another person, group, or organization on behalf of the covered individual when calculating the covered individual’s contribution toward a cost-sharing requirement. For example, if a covered individual receives a coupon for a drug which stipulates that the manufacturer of the drug will pay the copayment for the drug, then, under the bill, such a payment would have to be counted toward any cost-sharing requirement the covered individual’s health benefit plan might impose.

¹ R.C. 1751.68 and 3923.602, not in the bill.

² R.C. 1751.12 and 3923.811.

The bill exempts any payment made for a brand name drug when a generic equivalent exists, unless the prescriber determines the brand name drug to be medically necessary. The bill defines “generic equivalent” as a drug that is designated to be therapeutically equivalent, as indicated by the U.S. Food and Drug Administration’s publication titled “Approved Drug Products with Therapeutic Equivalence Evaluations.”³

Lastly, the bill requires a pharmacy benefit manager, in the performance of its contracted duties, to comply with the terms of applicable cost-sharing requirements regarding the prescribing, receipt, administration, or coverage of a prescription drug detailed in the bill. Under the bill, a “pharmacy benefit manager” is any person or entity that, pursuant to a contract or other relationship with an insurer, managed care organization, employer, or other third party, either directly or through an intermediary, manages the prescription drug benefit provided by the insurer, managed care organization, employer, or third party, including any of the following:

- The processing and payment of claims for covered prescription drugs;
- The performance of drug utilization review;
- The processing of drug prior authorization requests;
- The adjudication of appeals or grievances related to the prescription drug benefit;
- Contracting with network pharmacies;
- Controlling the cost of covered prescription drugs;
- The performance of any other duty directly or indirectly related to the processing or payment of claims for covered prescription drugs.⁴

The bill applies to health benefit plans delivered, issued for delivery, modified, or renewed on or after January 1, 2022.⁵

HISTORY

Action	Date
Introduced	02-18-21
Reported, H. Health	03-16-21

H0135-RH-134/ar

³ R.C. 1751.12(D)((H)(2) and 3923.811.

⁴ R.C. 3959.21.

⁵ Section 3.